Pospisilova, Kristyna
Siroka, Jitka
Karaskova, Eva
Hradsky, Ondrej
Lerchova, Tereza
Zarubova, Kristyna
Copova, Ivana
Gonsorcikova, Lucie
Velganova-Veghova, Maria
Francova, Irena
Urbanek, Lubor
Geryk, Milos
Mihal, Vladimir
Bronsky, Jiri
Funding for this research was provided by:
Ministerstvo Zdravotnictví Ceské Republiky (00064203, 0098892)
OP VVV ENOCH (CZ.02.1.01/0.0/0.0/16_019/0000868)
Article History
Accepted: 19 February 2021
First Online: 11 March 2021
Declarations
:
: This work was supported by Ministry of Health (Czech Republic) funding for the conceptual development of research organizations [00064203, University Hospital Motol, Prague, Czech Republic, and 0098892, University Hospital, Olomouc, Czech Republic], and the OP VVV ENOCH [CZ.02.1.01/0.0/0.0/16_019/0000868].
: Pospisilova K: lectures/congress fees/consultancy (outside submitted work)—MSD, Nutricia, Nestlé and Mead Johnsons; Karaskova E: lectures/congress fees/consultancy (outside submitted work)—MSD, AbbVie, Nutricia, and Nestlé; Hradsky O: lectures/congress fees/consultancy (outside submitted work)—MSD, AbbVie, Nutricia, Nestlé, Ferring, and Falk; Lerchova T: lectures/congress fees/consultancy (outside submitted work)—Nutricia, Ferring and Biocodex; Zarubova K: lectures/congress fees/consultancy (outside submitted work)—Nutricia and Nestlé; Velganova-Veghova M: congress fees/consultancy (outside submitted work)—MSD, AbbVie, Nutricia, and Nestlé; Bronsky J: lectures/congress fees/consultancy (outside submitted work)—MSD, AbbVie, Nutricia, Nestlé, Ferring, Biocodex, and Walmark; Gonsorcikova L, Francova I, Geryk M, Copova I, Mihal V, Siroka J, and Urbanek L report no conflicts of interest.
: The protocol for the observational study was approved by the Ethics Committees of the University Hospital Motol and the 2nd Medical Faculty of Charles University in Prague.
: Written informed consent was obtained from legal guardians before study enrollment.
: Non applicable.
: The study has been registered retrospectively in the ENCePP registry (encepp.eu), it can be found under the registration number EUPAS38918. Registered on 12 January 2021.
: The datasets analyzed during the current study are available from the corresponding author on reasonable request.
: The code is available from the corresponding author on reasonable request.
: PK: study design, literature search, data collection, patient recruitment, thiopurine metabolite measurement, data analysis, manuscript writing; SJ: data collection, thiopurine metabolite measurement and laboratory supervision, manuscript critical revision; KE: data collection, patient recruitment, manuscript critical revision; HO: study design, data analysis and interpretation, manuscript critical revision; LT: study design, data collection, patient recruitment, manuscript critical revision, ZK: data collection, patient recruitment, manuscript critical revision; CI: data collection, patient recruitment, manuscript critical revision; GL: data collection, patient recruitment, manuscript critical revision; V-VM: data collection, patient recruitment, manuscript critical revision; FI: data collection, infliximab levels and antibodies measurement supervision, manuscript critical revision; UL: thiopurine metabolite measurement—method optimization, data collection, manuscript critical revision; GM: data collection, patient recruitment, manuscript critical revision; Mihal V: data collection, supervision, manuscript critical revision; BJ: study design and supervision, literature search, manuscript writing. All authors read and approved the final manuscript.